# Sergey A. Kornilov, PhD

**Biomarker Validation & Trial Design Consulting | Translational Multi-Omics | Neurodegeneration & Metabolic Disease | Systems Biology | Behavioral Science | Machine Learning & A.I.**

[![LinkedIn](https://img.shields.io/badge/LinkedIn-0077B5?style=flat&logo=linkedin&logoColor=white)](https://www.linkedin.com/in/sergey-kornilov/)
[![Website](https://img.shields.io/badge/Consulting-kornilov.bio-2563eb?style=flat&logo=safari&logoColor=white)](https://kornilov.bio)
[![Email](https://img.shields.io/badge/Email-sergey.kornilov@biostochastics.com-00C300?style=flat&logo=mail.ru&logoColor=white)](mailto:sergey.kornilov@biostochastics.com)
[![Google Scholar](https://img.shields.io/badge/Google%20Scholar-4285F4?style=flat&logo=google-scholar&logoColor=white)](https://scholar.google.com/citations?user=xmwBz9EAAAAJ&hl=en)

---

## About

Independent consultant specializing in biomarker validation and clinical trial design for neurodegenerative disease, metabolic disease, and digital health programs. I focus on preventing costly failures by identifying confounding vulnerabilities and methodological flaws before trials enroll or studies publish.

**15+ years:** Multi-omic integration, translational neuroscience, clinical trial and observational study design, deep expertise in longitudinal studies

**Former:** Senior Research Scientist, Institute for Systems Biology (ISB; worked with Lee Hood and Mary Brunkow); Assistant Professor, University of Houston

**Editor:** Academia Neuroscience & Brain Research  

**Track record:** 65+ publications, $5M+ grant funding, $1.5M industry revenue

**Current focus:** Independent methodology validation | Biomarker platform assessment | Trial design audits | Investor due diligence | Translational program development

---

## Consulting Services

Available for:
- üî¨ **Biomarker validation audits** (multi-site study review, confounding detection)
- üìã **Trial design & protocol review** (endpoint validation, power analysis, regulatory risk)
- üß™ **Preclinical program guidance** (IND-enabling strategy, translational planning)
- üíº **Investor due diligence** (technical validation for biotech deals)
- üè• **Digital health & diagnostic validation** (algorithm validation, real-world performance)

---

## Recent Work

### üìä Nature Medicine ALS Biomarker Reanalysis (2025)

Independent methodological investigation revealing severe confounding in high-profile proteomics study:
- **72%** of published biomarkers failed geographic validation
- **99.9%** accuracy predicting technical artifacts (tube type) vs. disease
- **$15M+** estimated preventable follow-up costs

**Key finding:** Perfect confounding between diagnostic groups and technical factors created models learning artifacts instead of biology. Standard validation (98% pooled CV accuracy) missed this; geographic validation revealed deployment failure (77% AUC cross-site).

[**üìÑ Read full technical report with reproducible analysis ‚Üí**](https://biostochastics.quarto.pub/confounding-by-geography-and-anticoagulant-compromise-proposed-als-model/)

---

## Core Expertise

### üß¨ Multi-Omics & Systems Biology
- **Platforms:** Olink PEA, SomaScan, Metabolon, RNA-Seq (bulk/single-cell), WGS/WES
- **Integration:** WGCNA, MEGENA, MOFA, DIABLO, network-based approaches
- **Validation:** Geographic/leave-site-out CV, reverse prediction, stratified replication

### üß† Clinical Research & Translational Science
- **Diseases:** ALS, Alzheimer's, Parkinson's/LBD, MS, metabolic syndrome
- **Methods:** Biomarker validation, patient stratification, clinical trial design, RWE studies
- **Neurophysiology:** EEG/ERP, fMRI, eye tracking, digital biomarkers

### üíä Drug Development & Regulatory
- **Clinical:** Trial design (Phase 1/2), endpoint selection, power analysis, CDISC standards
- **Discovery:** Target ID, MoA characterization, AI-enabled discovery
- **Regulatory:** IND-enabling studies, FDA submission strategy, biomarker qualification

### üíª Technical Stack
- **Languages:** R (expert), Python, SQL, Stan
- **ML/Stats:** Statistical modeling, causal inference, longitudinal analysis, Bayesian methods
- **Infrastructure:** AWS/GCP, Docker, Shiny, reproducible pipelines (`targets`, `renv`)
- **Specialties:** Confounding detection, batch effect quantification, cross-site validation

---

## Open Source & Reproducibility

All consulting projects deliver:
- Reproducible analysis code (R/Python, version-controlled)
- Transparent statistical frameworks
- Documented methodology with validation tests

---

## Selected Publications

**65+ peer-reviewed publications** | [Full list on Google Scholar](https://scholar.google.com/citations?user=xmwBz9EAAAAJ&hl=en)

**Recent highlights:**

- **Kornilov, S.** (2025). Confounding by geography and anticoagulant compromises proposed ALS diagnostic model and biomarkers: Reanalysis of Chia et al. (2025). *Technical Report*. [Link](https://biostochastics.quarto.pub/confounding-by-geography-and-anticoagulant-compromise-proposed-als-model/)
  
- **Kornilov, S.** (2025). When Algorithms Learn to Discriminate. *Tech Policy Press*, [Link](https://www.techpolicy.press/when-algorithms-learn-to-discriminate-the-hidden-crisis-of-emergent-ableism/

- **Kornilov, S.**, Price, N., Gelinas, R., Brunkow, M, ... & Magis, A. (2024). Multi-Omic characterization of the effects of Ocrelizumab in patients with relapsing-remitting multiple sclerosis. *Journal of the Neurological Sciences*, 467, 123303. [10.1016/j.jns.2024.123303](https://doi.org/10.1016/j.jns.2024.123303)

- Heath, L., Earls, J., Magis, A., **Kornilov, S.**, ... Price, N. (2022). Manifestations of Alzheimer's disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. *Scientific Reports*, 12(6117). [10.1038/s41598-022-09825-2](https://doi.org/10.1038/s41598-022-09825-2)

- **Kornilov, S.**, Lucas, ... & Magis, A. (2020). Plasma levels of soluble ACE2 are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort. *Critical Care*, 24, 452. [10.1186/s13054-020-03141-9](https://doi.org/10.1186/s13054-020-03141-9)

- **Kornilov, S.**, Rakhlin, N., ... & Grigorenko, E.L. (2016). Genome-Wide Association and Exome Sequencing Study of Language Disorder in an Isolated Population. *Pediatrics*, 137(4). [10.1542/peds.2015-2469](https://doi.org/10.1542/peds.2015-2469)

[**View all publications ‚Üí**](https://scholar.google.com/citations?user=xmwBz9EAAAAJ&hl=en)

---

## Professional Background

**Founder & Principal** | Biostochastics LLC (2023-Present)  
*Independent biomarker validation and trial design consulting*

**Senior Research Scientist** | Institute for Systems Biology (2019-2024)  
*Multi-omic studies, clinical collaborations (Bryleos, Genentech, Gilead, Thorne, Sanitarium)*

**Statistical Geneticist** | Arivale Inc (2018-2019)  
*Precision wellness platform, longitudinal multi-omic analysis*

**Research Assistant Professor** | University of Houston (2017-2018)

---

## Education & Training

**PhD, Experimental Psychology** | University of Connecticut  
*Neurophysiological and genetic bases of developmental language disorder*

**PhD, Educational Psychology/Psychometrics** | Moscow State University

**Post-doctoral training in Molecular Genetics:** Yale School of Medicine & Baylor College of Medicine (Duncan Scholarship in Molecular and Human Genetics)

**Awards:** Outstanding Doctoral Dissertation Award (SRCD), GoldenHelix Award for Best Research, Isabelle Liberman Award

---

## Consulting Inquiries

**For biotech companies:**
- Biomarker validation before publication/trials
- Trial design audits (Phase 1/2 planning)
- Preclinical program guidance (IND-enabling strategy)

**For investors:**
- Technical due diligence on biomarker platforms
- Portfolio company methodology support
- Deal evaluation (multi-omics, diagnostics, digital health)

**For healthtech/diagnostics:**
- Algorithm validation and deployment feasibility
- Digital biomarker validation
- Regulatory pathway assessment

üìß **Contact:** [sergey.kornilov@biostochastics.com](mailto:sergey.kornilov@biostochastics.com)  
üíº **LinkedIn:** [linkedin.com/in/sergey-kornilov](https://www.linkedin.com/in/sergey-kornilov/)

---

*Available for consulting engagements and fractional advisory roles. Response time: <24 hours.*
